Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · IEX Real-Time Price · USD
6.21
-0.37 (-5.62%)
At close: Apr 12, 2024, 4:00 PM
6.24
+0.03 (0.48%)
After-hours: Apr 12, 2024, 7:59 PM EDT

Company Description

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases.

It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.

In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer.

It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited.

The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013.

Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Editas Medicine, Inc.
Editas Medicine logo
Country United States
Founded 2013
IPO Date Feb 3, 2016
Industry Biotechnology
Sector Healthcare
Employees 265
CEO Dr. Gilmore O'Neill M.D.

Contact Details

Address:
11 Hurley St.
Cambridge, Massachusetts 02141
United States
Phone 617-401-9000
Website editasmedicine.com

Stock Details

Ticker Symbol EDIT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001650664
CUSIP Number 28106W103
ISIN Number US28106W1036
Employer ID 46-4097528
SIC Code 2836

Key Executives

Name Position
Dr. Gilmore O'Neill M.D. President, Chief Executive Officer and Director
Dr. Baisong Mei M.D., Ph.D. Senior Vice President and Chief Medical Officer
Dr. Feng Zhang Ph.D. Co-Founder and Scientific Advisory Board Member
Dr. George McDonald Church Ph.D. Co-Founder and Scientific Advisory Board Member
Dr. J. Keith Joung M.D., Ph.D. Co-Founder and Scientific Advisory Board Member
Dr. David R. Liu Ph.D. Co-Founder and Scientific Advisory Board Member
Dr. Linda C. Burkly Ph.D. Executive Vice President and Chief Scientific Officer
Cristi Barnett Corporate Communications and Investor Relations
Charlene Stern J.D., Ph.D. Executive Vice President and General Counsel
Linea Aspesi Executive Vice President and Chief People Officer

Latest SEC Filings

Date Type Title
Apr 10, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Mar 4, 2024 144 Filing
Feb 28, 2024 S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers
Feb 28, 2024 S-8 Securities to be offered to employees in employee benefit plans
Feb 28, 2024 10-K Annual Report
Feb 28, 2024 8-K Current Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 24, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 10, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals